Table of Contents_x000D_
List of Tables_x000D_
List of Figures_x000D_
1 Introduction_x000D_
1.1 What Is This Report About?_x000D_
1.2 Metabolic Disorders Market Segmentation_x000D_
1.3 Definitions of Markets Covered in the Report_x000D_
2 Metabolic Disorders Market, EU5_x000D_
2.1 Metabolic Disorders Market, EU5, Revenue ($m), 2024-2036_x000D_
2.2 Metabolic Disorders Market, EU5, Revenue ($m), 2024-2036_x000D_
2.3 Metabolic Disorders Market, EU5, Volume (Units), 2024-2036_x000D_
2.4 Metabolic Disorders Market, EU5, Volume (Units), 2024-2036_x000D_
2.5 Metabolic Disorders Market, EU5, Company Share by Revenue ($m), 2025_x000D_
3 Metabolic Disorders Market, France_x000D_
3.1 Metabolic Disorders Market, France, Revenue ($m), 2024-2036_x000D_
3.1.1 Cholesterol Tests Market, France, Revenue ($m), by Segment, 2024-2036_x000D_
3.1.2 Diabetes Assays Market, France, Revenue ($m), by Segment, 2024-2036_x000D_
3.2 Metabolic Disorders Market, France, Volume (Units), 2024-2036_x000D_
3.2.1 Cholesterol Tests Market, France, Volume (Units), by Segment, 2024-2036_x000D_
3.2.2 Diabetes Assays Market, France, Volume (Units), by Segment, 2024-2036_x000D_
3.3 Metabolic Disorders Market, France, Average Price ($), 2024-2036_x000D_
3.4 Metabolic Disorders Market, France, Company Share by Revenue ($m), 2025_x000D_
4 Metabolic Disorders Market, Germany_x000D_
4.1 Metabolic Disorders Market, Germany, Revenue ($m), 2024-2036_x000D_
4.1.1 Cholesterol Tests Market, Germany, Revenue ($m), by Segment, 2024-2036_x000D_
4.1.2 Diabetes Assays Market, Germany, Revenue ($m), by Segment, 2024-2036_x000D_
4.2 Metabolic Disorders Market, Germany, Volume (Units), 2024-2036_x000D_
4.2.1 Cholesterol Tests Market, Germany, Volume (Units), by Segment, 2024-2036_x000D_
4.2.2 Diabetes Assays Market, Germany, Volume (Units), by Segment, 2024-2036_x000D_
4.3 Metabolic Disorders Market, Germany, Average Price ($), 2024-2036_x000D_
4.4 Metabolic Disorders Market, Germany, Company Share by Revenue ($m), 2025_x000D_
5 Metabolic Disorders Market, Italy_x000D_
5.1 Metabolic Disorders Market, Italy, Revenue ($m), 2024-2036_x000D_
5.1.1 Cholesterol Tests Market, Italy, Revenue ($m), by Segment, 2024-2036_x000D_
5.1.2 Diabetes Assays Market, Italy, Revenue ($m), by Segment, 2024-2036_x000D_
5.2 Metabolic Disorders Market, Italy, Volume (Units), 2024-2036_x000D_
5.2.1 Cholesterol Tests Market, Italy, Volume (Units), by Segment, 2024-2036_x000D_
5.2.2 Diabetes Assays Market, Italy, Volume (Units), by Segment, 2024-2036_x000D_
5.3 Metabolic Disorders Market, Italy, Average Price ($), 2024-2036_x000D_
5.4 Metabolic Disorders Market, Italy, Company Share by Revenue ($m), 2025_x000D_
6 Metabolic Disorders Market, Spain_x000D_
6.1 Metabolic Disorders Market, Spain, Revenue ($m), 2024-2036_x000D_
6.1.1 Cholesterol Tests Market, Spain, Revenue ($m), by Segment, 2024-2036_x000D_
6.1.2 Diabetes Assays Market, Spain, Revenue ($m), by Segment, 2024-2036_x000D_
6.2 Metabolic Disorders Market, Spain, Volume (Units), 2024-2036_x000D_
6.2.1 Cholesterol Tests Market, Spain, Volume (Units), by Segment, 2024-2036_x000D_
6.2.2 Diabetes Assays Market, Spain, Volume (Units), by Segment, 2024-2036_x000D_
6.3 Metabolic Disorders Market, Spain, Average Price ($), 2024-2036_x000D_
6.4 Metabolic Disorders Market, Spain, Company Share by Revenue ($m), 2025_x000D_
7 Metabolic Disorders Market, United Kingdom_x000D_
7.1 Metabolic Disorders Market, United Kingdom, Revenue ($m), 2024-2036_x000D_
7.1.1 Cholesterol Tests Market, United Kingdom, Revenue ($m), by Segment, 2024-2036_x000D_
7.1.2 Diabetes Assays Market, United Kingdom, Revenue ($m), by Segment, 2024-2036_x000D_
7.2 Metabolic Disorders Market, United Kingdom, Volume (Units), 2024-2036_x000D_
7.2.1 Cholesterol Tests Market, United Kingdom, Volume (Units), by Segment, 2024-2036_x000D_
7.2.2 Diabetes Assays Market, United Kingdom, Volume (Units), by Segment, 2024-2036_x000D_
7.3 Metabolic Disorders Market, United Kingdom, Average Price ($), 2024-2036_x000D_
7.4 Metabolic Disorders Market, United Kingdom, Company Share by Revenue ($m), 2025_x000D_
8 Metabolic Disorders Market Pipeline Products_x000D_
8.1 Metabolic Disorders Market Pipeline Products_x000D_
8.2 Metabolic Disorders – Pipeline Products by Stage of Development_x000D_
8.3 Metabolic Disorders – Pipeline Products by Segment_x000D_
8.4 Metabolic Disorders – Pipeline Products by Territory_x000D_
8.5 Metabolic Disorders – Pipeline Products by Regulatory Path_x000D_
8.6 Metabolic Disorders – Pipeline Products by Estimated Approval Date_x000D_
9 Overview of Key Companies in EU5 Metabolic Disorders Market_x000D_
9.1 Roche Diagnostics International Ltd_x000D_
9.1.1 Company Overview_x000D_
9.2 Siemens Healthineers AG_x000D_
9.2.1 Company Overview_x000D_
9.3 Abbott Laboratories_x000D_
9.3.1 Company Overview_x000D_
9.4 Beckman Coulter Inc_x000D_
9.4.1 Company Overview_x000D_
9.5 Ortho Clinical Diagnostics Holdings Ltd (Inactive)_x000D_
9.5.1 Company Overview_x000D_
9.6 Danaher Corp_x000D_
9.6.1 Company Overview_x000D_
10 Recent Developments_x000D_
10.1 Corporate Communications_x000D_
10.1.1 Nov 05, 2025: Waardenburg Syndrome and Piebaldism_x000D_
10.1.2 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research_x000D_
10.1.3 Oct 24, 2025: EU Invests in Umeå Research_x000D_
10.1.4 Sep 10, 2025: NWO Grants €6.8 Million to META-IMMUNOTYPES Consortium Led by Dr. Garcia Vallejo_x000D_
10.1.5 Aug 12, 2025: Markus Rohrwild Appointed New CEO of Gubra in a Planned Succession Process_x000D_
10.1.6 Jun 12, 2025: Relief Therapeutics Announces Results of Annual General Meeting_x000D_
10.2 Other Significant Developments_x000D_
10.2.1 Nov 05, 2025: Skolkovo Launches Grant Support for Technological Leaders_x000D_
10.2.2 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research_x000D_
10.2.3 Oct 24, 2025: EU Invests in Umeå Research_x000D_
10.2.4 Sep 10, 2025: NWO Grants €6.8 Million to META-IMMUNOTYPES Consortium Led by Dr. Garcia Vallejo_x000D_
10.3 Product News_x000D_
10.3.1 Nov 17, 2025: ScreenCell Standardizes CTC Isolation Kits to Two Filtration Units_x000D_
10.3.2 Nov 14, 2025: Scientists Invent New Method for Producing Platelet-Producing Cells from Stem Cells_x000D_
10.3.3 Nov 11, 2025: Samsung Active Asset Management Launches KoAct US Biohealthcare Active ETF Benchmarking the Solactive US Biohealthcare Index_x000D_
10.3.4 Oct 30, 2025: FNCC RR Showcases Innovative Developments at All-Russian Exhibition_x000D_
10.3.5 Oct 10, 2025: An International Project Employs 'Resurrected' Ancestral Enzymes for Cancer Prevention and Neurobiology Studies_x000D_
10.3.6 Sep 19, 2025: Boditech Med Launches Advanced Diabetes Diagnostics at EASD 2025_x000D_
10.3.7 Sep 08, 2025: New metabolic clock could help detect early signs of disease and accelerated aging_x000D_
10.4 Research And Development_x000D_
10.4.1 Nov 05, 2025: Skolkovo Launches Grant Support for Technological Leaders_x000D_
10.4.2 Oct 10, 2025: An International Project Employs 'Resurrected' Ancestral Enzymes for Cancer Prevention and Neurobiology Studies_x000D_
10.5 Strategy And Business Planning_x000D_
10.5.1 Nov 17, 2025: UMA Joins Technological Platforms to Boost Innovation_x000D_
10.5.2 Nov 11, 2025: Samsung Active Asset Management Launches KoAct US Biohealthcare Active ETF Benchmarking the Solactive US Biohealthcare Index_x000D_
10.5.3 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research_x000D_
11 Appendix_x000D_
11.1 Research Methodology_x000D_
11.1.1 Coverage_x000D_
11.1.2 Secondary Research_x000D_
11.1.3 Primary Research_x000D_
11.1.4 Market Modeling and Forecasting_x000D_
11.1.5 Company Share Analysis_x000D_
11.1.6 Benchmarking_x000D_
11.2 GlobalData Consulting_x000D_
11.3 Contact Us_x000D_
11.4 Disclaimer